請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78702完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陶秘華 | |
| dc.contributor.author | Tzu-Jiun Kuo | en |
| dc.contributor.author | 郭姿均 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:13:16Z | - |
| dc.date.available | 2024-08-28 | |
| dc.date.copyright | 2019-08-28 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-08-01 | |
| dc.identifier.citation | 1. Dugger, S.A., A. Platt, and D.B. Goldstein, Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2017. 17: p. 183.
2. Shultz, L.D., et al., Humanized mouse models of immunological diseases and precision medicine. Mamm Genome, 2019. 3. Rongvaux, A., et al., Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol, 2013. 31: p. 635-674. 4. Mestas, J. and C.C. Hughes, Of mice and not men: differences between mouse and human immunology. J Immunol, 2004. 172(5): p. 2731-8. 5. Barnaba, V., et al., Professional presentation of antigen by activated human T cells. Eur J Immunol, 1994. 24(1): p. 71-5. 6. Taams, L.S., W. van Eden, and M.H. Wauben, Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions. Eur J Immunol, 1999. 29(5): p. 1543-50. 7. Perez Horta, Z., et al., Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines. Oncoimmunology, 2019. 8(6): p. e1238538. 8. De La Rochere, P., et al., Humanized Mice for the Study of Immuno-Oncology. Trends in Immunology, 2018. 39(9): p. 748-763. 9. Bijlsma, R.M., et al., Cancer patients' intentions towards receiving unsolicited genetic information obtained using next-generation sequencing. Fam Cancer, 2018. 17(2): p. 309-316. 10. Ito, R., et al., Current advances in humanized mouse models. Cell Mol Immunol, 2012. 9(3): p. 208-14. 11. Manz, M.G., Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity, 2007. 26(5): p. 537-41. 12. Shultz, L.D., et al., Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol, 2012. 12(11): p. 786-98. 13. Bosma, G.C., R.P. Custer, and M.J. Bosma, A severe combined immunodeficiency mutation in the mouse. Nature, 1983. 301(5900): p. 527-30. 14. Kamel-Reid, S. and J.E. Dick, Engraftment of immune-deficient mice with human hematopoietic stem cells. Science, 1988. 242(4886): p. 1706-9. 15. McCune, J.M., et al., The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science, 1988. 241(4873): p. 1632-9. 16. Mosier, D.E., et al., Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature, 1988. 335(6187): p. 256-9. 17. Blunt, T., et al., Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A, 1996. 93(19): p. 10285-90. 18. Mombaerts, P., et al., RAG-1-deficient mice have no mature B and T lymphocytes. Cell, 1992. 68(5): p. 869-77. 19. Shinkai, Y., et al., RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell, 1992. 68(5): p. 855-67. 20. Hesselton, R.M., et al., High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis, 1995. 172(4): p. 974-82. 21. Lowry, P.A., et al., Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol Blood Marrow Transplant, 1996. 2(1): p. 15-23. 22. Koyanagi, Y., et al., High levels of viremia in hu-PBL-NOD-scid mice with HIV-1 infection. Leukemia, 1997. 11 Suppl 3: p. 109-12. 23. Shultz, L.D., et al., Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol, 1995. 154(1): p. 180-91. 24. Barclay, A.N. and M.H. Brown, The SIRP family of receptors and immune regulation. Nat Rev Immunol, 2006. 6(6): p. 457-64. 25. Ito, M., et al., NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood, 2002. 100(9): p. 3175-82. 26. Shultz, L.D., et al., Human Lymphoid and Myeloid Cell Development in NOD/LtSz-<em>scid IL2R</em>γ<sup><em>null</em></sup> Mice Engrafted with Mobilized Human Hemopoietic Stem Cells. The Journal of Immunology, 2005. 174(10): p. 6477-6489. 27. Sugamura, K., et al., The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol, 1996. 14: p. 179-205. 28. Greiner, D.L., R.A. Hesselton, and L.D. Shultz, SCID mouse models of human stem cell engraftment. Stem Cells, 1998. 16(3): p. 166-77. 29. Melkus, M.W., et al., Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med, 2006. 12(11): p. 1316-22. 30. Nikzad, R., et al., Human natural killer cells mediate adaptive immunity to viral antigens. Sci Immunol, 2019. 4(35). 31. Theocharides, A.P.A. and M.G. Manz, Finally: development of humanized lymph nodes. Nat Methods, 2018. 15(8): p. 580-582. 32. Li, Y., et al., A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. European Journal of Immunology, 2016. 46(5): p. 1291-1299. 33. Lopez-Lastra, S., et al., A functional DC cross talk promotes human ILC homeostasis in humanized mice. Blood Adv, 2017. 1(10): p. 601-614. 34. Yu, H., et al., A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood, 2017. 129(8): p. 959-969. 35. Rongvaux, A., et al., Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol, 2014. 32(4): p. 364-72. 36. Billerbeck, E., et al., Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood, 2011. 117(11): p. 3076-86. 37. Herndler-Brandstetter, D., et al., Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci U S A, 2017. 114(45): p. E9626-e9634. 38. Katano, I., et al., Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Scientific Reports, 2017. 7(1): p. 17230. 39. Becker, P.D., et al., Generation of human antigen-specific monoclonal IgM antibodies using vaccinated 'human immune system' mice. PLoS One, 2010. 5(10). 40. Kametani, Y., et al., Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse. Exp Hematol, 2006. 34(9): p. 1240-8. 41. Matsumura, T., et al., Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells. Exp Hematol, 2003. 31(9): p. 789-97. 42. Danner, R., et al., Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One, 2011. 6(5): p. e19826. 43. Watanabe, Y., et al., The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice). Int Immunol, 2009. 21(7): p. 843-58. 44. Li, Y., et al., A human immune system mouse model with robust lymph node development. Nat Methods, 2018. 15(8): p. 623-630. 45. Choi, Y., et al., Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med, 2018. 50(8): p. 99. 46. Hahn, S.A., et al., Translating Treg Therapy in Humanized Mice. Frontiers in Immunology, 2015. 6(623). 47. Zeng, Y., et al., Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells. PLoS One, 2017. 12(4): p. e0173754. 48. Yaguchi, T., et al., Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cell Mol Immunol, 2017. 49. Brehm, M.A., et al., Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. Faseb j, 2018: p. fj201800636R. 50. Willinger, T., et al., Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends Immunol, 2011. 32(7): p. 321-7. 51. Chang, C.M., et al., Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist. Hum Gene Ther, 2010. 21(5): p. 611-21. 52. Wang, D., P.W.L. Tai, and G. Gao, Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019. 18(5): p. 358-378. 53. Xiao, X., J. Li, and R.J. Samulski, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998. 72(3): p. 2224-32. 54. Chen, C.C., et al., Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther, 2009. 17(2): p. 352-9. 55. Ai, J., et al., Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Sci Rep, 2017. 7: p. 40336. 56. Zincarelli, C., et al., Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008. 16(6): p. 1073-80. 57. Wang, J., et al., Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res, 2016. 44(3): p. e30. 58. O'Connell, R.M., et al., Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations. PLoS One, 2010. 5(8): p. e12009. 59. van Lent, A.U., et al., IL-7 enhances thymic human T cell development in 'human immune system' Rag2-/-IL-2Rgammac-/- mice without affecting peripheral T cell homeostasis. J Immunol, 2009. 183(12): p. 7645-55. 60. Chen, Q., et al., GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation. J Immunol, 2012. 189(11): p. 5223-9. 61. Schmidt, M.R., et al., Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice. PLoS One, 2008. 3(9): p. e3192. 62. Alegre, M.L., et al., Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol, 1994. 153(6): p. 2738-49. 63. Ghosn, S., et al., Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model. Frontiers in Immunology, 2018. 9(601). 64. Su, K.Y., et al., Efficient Culture of Human Naive and Memory B Cells for Use as APCs. J Immunol, 2016. 197(10): p. 4163-4176. 65. Su, K.-Y., The Prospects of Human CD40L-Activated Antigen-Presenting B Cells. Vol. 1. 2016. 66. Naito, M., et al., CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother, 2013. 62(2): p. 347-57. 67. Garcia-Marquez, M.A., et al., A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. Cytotherapy, 2014. 16(11): p. 1537-1544. 68. Yan, J., et al., Targeting antigen to CD19 on B cells efficiently activates T cells. International Immunology, 2005. 17(7): p. 869-877. 69. Sumida, S.M., et al., Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest, 2004. 114(9): p. 1334-42. 70. Bossen, C., et al., Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem, 2006. 281(20): p. 13964-71. 71. Giesecke, C., et al., Tissue Distribution and Dependence of Responsiveness of Human Antigen-Specific Memory B Cells. The Journal of Immunology, 2014. 192(7): p. 3091-3100. 72. Choi, P. and H. Reiser, IL-4: role in disease and regulation of production. Clinical and experimental immunology, 1998. 113(3): p. 317-319. 73. Silva-Filho, J.L., C. Caruso-Neves, and A.A.S. Pinheiro, IL-4: an important cytokine in determining the fate of T cells. Biophysical reviews, 2014. 6(1): p. 111-118. 74. Kametani, Y., et al., NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination. PLoS One, 2017. 12(6): p. e0179239. 75. Mackay, F. and J.L. Browning, BAFF: a fundamental survival factor for B cells. Nat Rev Immunol, 2002. 2(7): p. 465-75. 76. Mackay, F., et al., BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol, 2003. 21: p. 231-64. 77. Yacoub-Youssef, H., et al., Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of human spleen cells. Transpl Immunol, 2005. 15(2): p. 157-64. 78. Brams, P., et al., Antigen-specific IgG responses from naive human splenocytes: in vitro priming followed by antigen boost in the SCID mouse. J Immunol, 1998. 160(5): p. 2051-8. 79. Chamat, S., et al., Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis, 1999. 180(2): p. 268-77. 80. Bouharoun-Tayoun, H., et al., Plasmodium falciparum: production of human antibodies specific for the MSP-3 protein in the Hu-SPL-SCID Mouse. Experimental Parasitology, 2004. 108(1): p. 47-52. 81. Banchereau, J. and F. Rousset, Growing human B lymphocytes in the CD40 system. Nature, 1991. 353(6345): p. 678-9. 82. Kikushige, Y., et al., Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol, 2008. 180(11): p. 7358-67. 83. Karsunky, H., et al., Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med, 2003. 198(2): p. 305-13. 84. Liu, K., et al., In vivo analysis of dendritic cell development and homeostasis. Science, 2009. 324(5925): p. 392-7. 85. Waskow, C., et al., The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol, 2008. 9(6): p. 676-83. 86. Breton, G., et al., Circulating precursors of human CD1c<sup>+</sup> and CD141<sup>+</sup> dendritic cells. The Journal of Experimental Medicine, 2015. 212(3): p. 401-413. 87. Maraskovsky, E., et al., Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. The Journal of Experimental Medicine, 1996. 184(5): p. 1953-1962. 88. Serreze, D.V., J.W. Gaedeke, and E.H. Leiter, Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A, 1993. 90(20): p. 9625-9. 89. Pearson, T., et al., Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol, 2003. 171(1): p. 185-95. 90. Eidenschenk, C., et al., Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells. Proceedings of the National Academy of Sciences, 2010. 107(21): p. 9759-9764. 91. Roopenian, D.C. and S. Akilesh, FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 2007. 7(9): p. 715-25. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78702 | - |
| dc.description.abstract | 人類免疫系統(HIS)小鼠模式是研究人類免疫治療的重要臨床前(preclinical)工具。使用人類周邊血液單核細胞(PBMC)在小鼠體內所重建的人類免疫系統，較能模擬病人的當前免疫狀態。然而，當前植入人類PBMC的HIS (Hu-PBL HIS)小鼠模式，有兩大限制：(1) 嚴重的異種移植物對抗宿主疾病(xeno-GVHD)，使小鼠提早死亡，而無法進行長期的免疫分析。(2) T細胞以外的人類免疫細胞族群無法在小鼠體內被完整重建。本篇研究的目的，是改善Hu-PBL HIS小鼠模式的兩大限制，期許在小鼠體內重建抗原呈現細胞，並使Hu-PBL HIS小鼠模式在免除xeno-GVHD時，能有效的發生抗原專一性免疫反應。為了避免xeno-GVHD的發生，我們使用了主要組織相容性複合物第一型與第二型缺失(MHC class I- and class II-deficient)的免疫缺陷NSG (NSG-dKO)小鼠，作為移植人類PBMC的宿主，NSG-dKO小鼠的種群擴增與分型正在進行。同時，我們用NSG小鼠當作宿主，探討提供人類細胞激素是否能促進在Hu-PBL HIS小鼠模式中移植率很低的免疫細胞族群的重建，例如：B細胞以及樹突細胞。腺相關病毒(AAV)載體可持續且全身性在體內表現基因，我們利用AAV載體在Hu-PBL HIS小鼠模式中表現人類細胞激素，證明人類細胞激素可以調控人類以及小鼠的免疫細胞。其中，介白素-4 (IL-4)可促進CD4 T細胞的增生以及抑制xeno-GVHD。植入人類脾臟細胞的HIS (Hu-SPL HIS)小鼠模式，具備人類細胞免疫以及體液免疫反應，為了仿造Hu-SPL HIS小鼠模式，本篇研究專注於使用人類IL-4, CD40配體 (CD40L)以及FMS樣酪氨酸激酶3配體 (Flt3L)來促進B細胞和樹突細胞的體內增生。但是，我們發現在NSG小鼠體內表現人類Flt3L會使小鼠的吞噬細胞大量增生，且此現象與人類PBMC的移植率呈現負相關。此策略還需要經過一些改善，才能看見人類細胞激素促進B細胞和樹突細胞的體內增生與存活的效果。本篇研究提出了新穎且技術上可行的方法，藉由表現人類IL-4, CD40L與Flt3L來改善抗原呈現細胞在Hu-PBL HIS小鼠模式中的低移植率。加上使用NSG-dKO小鼠作為宿主，此小鼠模式期望能在沒有xeno-GVHD的情況下，用來研究個人化的抗原專一性免疫反應。 | zh_TW |
| dc.description.abstract | Immunodeficient mice engrafted with human immune cells (HIS mice) serve as valuable tools for preclinical evaluation of immunotherapies. The use of human peripheral-blood mononuclear cells (PBMCs) to reconstitute human immune system in HIS mice enables the analysis of current immune status of individual patient. However, there are two major limitations of PBMC-engrafted HIS mouse model: (1) The rapid development of lethal xenogeneic graft-versus-host disease (GVHD) that hinders long-term and precise immune analysis, (2) incomplete reconstitution of immune subpopulations with few B cells and myeloid cells engrafted. We aimed to generate modified human PBMC-engrafted HIS mice with improved reconstitution of antigen presenting cells for the study of human antigen-specific immune response in the absence of xenogeneic GVHD. To avoid xenogeneic GVHD, we have obtained MHC class I- and class II-deficient NOD-scid IL-2rγnull (NSG-dKO) mice from collaborators as the host of human PBMC. Colony expansion and characterization of NSG-dKO mice is currently ongoing. In the meantime, we used NSG mice as the host to investigate whether supplementary of human cytokines can improve the poor engraftment rate of certain immune subpopulations in Hu-PBL HIS mice. Taking advantage of AAV vectors that allow sustained systemically expression of human cytokines in vivo, we demonstrated that AAV-delivered human cytokines regulated both murine and human leukocytes in HIS mice. The expression of human IL-4 significantly increased CD4 T cell expansion and suppressed GVHD. To mimic the features of human splenocyte-engrafted HIS mice, a model displays profound human humoral and cellular immune responses, we focused on expanding human B cells and dendritic cells using IL-4, CD40L and Flt3L. Interestingly, we found that the cell number of mouse phagocytes were greatly increased in human Flt3L expressing NSG mice. In addition, the phenomenon was negatively correlated with human PBMC engraftment rate. Modifications were needed to see the effect of human cytokines on supporting in vivo expansion and survival of B cell and dendritic cells. Collectively, we presented novel and technically feasible strategies to enhance the engraftment of antigen presenting cells in human PBMC-reconstituted HIS model by delivering human IL-4, CD40L and Flt3L. When combined with murine MHC deficiency, the HIS model will be able to recapitulate the personalized human antigen-specific immune responses without signs of xeno-GVHD. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:13:16Z (GMT). No. of bitstreams: 1 ntu-108-R06445108-1.pdf: 4241908 bytes, checksum: 4c5e651a4ff29a807c52ac59c7aa0677 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | Table of Contents
口試委員審定書 i 誌謝 ii 中文摘要 iii Abstract iv Tables ix Figures x Appendix xi 1. Introduction 1 1.1 A need of Human Immune System (HIS) mice for personalized preclinical studies 1 1.2 Model systems for engrafting human immune system 2 1.2.1 Immunodeficient host mice 3 1.3 Hu-CD34+ HSC HIS model 4 1.3.1 Advances in Hu-CD34+ HSC HIS model 5 1.3.2 Continuing limitations and current strategies to improve Hu-HSC HIS model 6 1.3.3 Hu-HSC HIS model is not a suitable preclinical platform for precision medicine 7 1.4 Hu-PBL HIS model 7 1.4.1 Strategies to improve Hu-PBL HIS model 8 1.5 Aim of this study 9 2. Materials and Methods 10 2.1 Mice and cell line 10 2.2 Double-stranded AAV vectors 11 2.3 Human cytokines and costimulatory molecules expression 11 2.4 EGFP signal analysis 12 2.5 Collection and engraftment of human PBMC 12 2.6 Flow Cytometry 12 2.7 Isolation of mouse splenocytes, BM and intrahepatic leukocytes 13 2.8 Determination of serum human IgG and IgM 14 2.9 in vitro B cell expansion 14 2.10 Statistics 15 3. Results 16 3.1 Hu-PBL HIS mouse model derived from human PBMC transplantation into NSG mice 16 3.2 NSG mice deficient in MHC class I and II expression 17 3.3 AAV as a vector for human cytokine delivery 17 3.3.1 AAV in vivo transduction and expression 17 3.3.2 rAAV8 systemically expressed human cytokines 18 3.4 Human cytokine delivery to enhance the engraftment of immune subpopulations in Hu-PBL HIS model 19 3.4.1 Delivered human cytokines that support CD34+ HSC development into PBMC transplanted NSG 19 3.4.2 Cytokine supplementation strategy tailored to mature human leukocytes 20 3.5 Recapitulate in vitro cell expansion technique in vivo 21 3.5.1 Recombinant human IL-4 and CD40L activate and expand B cells in vitro 21 3.5.2 Construction of AAV-human cytokines for in vivo expansion of B cells and dendritic cells from peripheral blood 21 3.5.3 Failure of B cell reconstitution in human IL-4, CD40L expressing NSG mice 22 3.6 Human Flt3L negatively affects human PBMC engraftment in NSG mice 23 3.6.1 hFlt3L expression decreased human PBMC engraftment rate 23 3.6.2 hFlt3L induced the expansion of NSG phagocytic cells 24 3.7 Increase B cell percentage of total injected human cells 25 4. Discussion 26 4.1 Effects of cytokines on human PBMC 26 4.2 HIS model engrafted with human spleen cells 27 4.3 Two strategies to enhance B cell engraftment 28 4.4 DC expansion from peripheral blood by Flt3L 29 4.5 hFlt3L activates and expands murine phagocytic cells 30 4.6 Future directions 31 4.7 Conclusion 32 5. References 34 6. Tables 43 7. Figures 44 8. Appendix 75 | |
| dc.language.iso | zh-TW | |
| dc.subject | 抗原呈現細胞 | zh_TW |
| dc.subject | 人類免疫系統小鼠模式 | zh_TW |
| dc.subject | 主要組織相容性複合物缺失 | zh_TW |
| dc.subject | 移植物對抗宿主疾病 | zh_TW |
| dc.subject | 周邊血液單核細胞 | zh_TW |
| dc.subject | 細胞激素 | zh_TW |
| dc.subject | cytokine | en |
| dc.subject | MHC deficiency | en |
| dc.subject | GVHD | en |
| dc.subject | PBMC | en |
| dc.subject | Human immune system mice | en |
| dc.subject | antigen presenting cell | en |
| dc.title | 改善人類周邊血液單核細胞建立的人類免疫系統小鼠模式 | zh_TW |
| dc.title | Generation of improved human immune system mice reconstituted with peripheral blood mononuclear cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林淑華,繆希椿 | |
| dc.subject.keyword | 人類免疫系統小鼠模式,主要組織相容性複合物缺失,移植物對抗宿主疾病,周邊血液單核細胞,細胞激素,抗原呈現細胞, | zh_TW |
| dc.subject.keyword | Human immune system mice,MHC deficiency,GVHD,PBMC,cytokine,antigen presenting cell, | en |
| dc.relation.page | 76 | |
| dc.identifier.doi | 10.6342/NTU201902352 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-08-01 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2024-08-28 | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-R06445108-1.pdf 未授權公開取用 | 4.14 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。